Abiopharma

🔍 Clifton R. LaDuane (Executive)

Company: ZEVRA THERAPEUTICS, INC. (ZVRA)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 140,667 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 192,028.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 48,513 shares of Common Stock at $8.96 per share (Direct)
  Date: 2025-12-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 143,515.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 86,667 shares of Restricted Stock Unit (Derivative)
  Date: 2025-12-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F4, F4
• Sold 34,000 shares of Restricted Stock Unit (Derivative)
  Date: 2025-12-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F4, F4
• Sold 20,000 shares of Performance Stock Unit (Derivative)
  Date: 2025-12-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F4, F4

Footnotes:

• F1: Shares issued upon vesting of restricted stock units and performance stock units on December 31, 2025.
• F2: Shares withheld to cover withholding taxes for the vested restricted stock units and performance stock units.
• F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
• F4: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025.
• F5: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.